This provider's $11.8M in total Medicare payments ranks in the 99th percentile of Nuclear Medicine providers nationally.
Medicare payments to this provider grew 54% from 2014 to 2023.
64% of their billing comes from a single procedure code (78815 — Nuclear medicine study with CT imaging skull base to mid-thigh).
AI-generated analysis based on Medicare payment data.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $548.90 | $232.79 | 2.36x | $316.11 | $1.2M | 2.7K | 2.5K |
| 2015 | $549.21 | $235.66 | 2.33x | $313.55 | $535.7K | 2.5K | 2.3K |
| 2016 | $611.78 | $247.12 | 2.48x | $364.66 | $623.6K | 3.2K | 3.0K |
| 2017 | $644.85 | $270.70 | 2.38x | $374.15 | $732.7K | 3.4K | 3.2K |
| 2018 | $594.37 | $259.45 | 2.29x | $334.92 | $921.7K | 3.6K | 3.3K |
| 2019 | $538.83 | $211.52 | 2.55x | $327.31 | $1.1M | 2.8K | 2.6K |
| 2020 | $608.57 | $269.65 | 2.26x | $338.92 | $1.2M | 2.6K | 2.5K |
| 2021 | $687.75 | $307.47 | 2.24x | $380.28 | $1.7M | 2.9K | 2.6K |
| 2022 | $784.55 | $351.60 | 2.23x | $432.95 | $1.9M | 3.5K | 3.2K |
| 2023 | $637.83 | $281.17 | 2.27x | $356.66 | $1.9M | 3.6K | 3.3K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 78815 | Nuclear medicine study with CT imaging skull base to mid-thigh | 6.1K | $7.5M | $1.2K | 2.45x |
| 78816 | Nuclear medicine study with CT imaging whole body | 1.1K | $1.3M | $1.3K | 2.37x |
| 78306 | Bone and/or joint imaging, whole body | 4.0K | $1.0M | $255.09 | 1.74x |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 6.0K | $383.2K | $63.51 | 1.26x |
| 78264 | Stomach emptying study | 808 | $244.4K | $302.52 | 1.45x |
| 78315 | Bone and/or joint imaging, 3 phase study | 631 | $204.4K | $323.86 | 1.52x |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | 450 | $199.0K | $442.25 | 3.39x |
| 78227 | Imaging of liver and bile duct system with use of drugs | 436 | $170.3K | $390.56 | 2.45x |
| 78014 | Nuclear medicine imaging for thyroid uptake measurements | 454 | $100.5K | $221.34 | 2.39x |
| 78071 | Imaging of parathyroid with nuclear medicine study | 288 | $95.1K | $330.28 | 2.39x |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 4.6K | $70.1K | $15.11 | 1.28x |
| 78708 | Nuclear medicine study of kidney with assessment of blood flow and function | 394 | $63.8K | $162.01 | 3.34x |
| 78226 | Imaging of liver and bile duct system | 205 | $63.3K | $308.98 | 2.27x |
| 78608 | Nuclear medicine study of brain with metabolic evaluation | 38 | $58.5K | $1.5K | 2.29x |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 808 | $42.4K | $52.50 | 1.27x |
| 78472 | Nuclear medicine study of heart wall motion at rest or stress with evaluation of blood ejection from heart, single study | 169 | $36.7K | $217.24 | 2.52x |
| J2805 | Injection, sincalide, 5 micrograms | 419 | $34.2K | $81.72 | 1.50x |
| A9562 | Technetium tc-99m mertiatide, diagnostic, per study dose, up to 15 millicuries | 141 | $29.7K | $210.30 | 1.34x |
| 93015 | Exercise or drug-induced heart and blood vessel stress test with EKG monitoring, physician supervision, interpretation, and report | 470 | $27.6K | $58.74 | 5.62x |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 787 | $25.2K | $32.07 | 1.29x |
This provider submits charges 2.3 times higher than what Medicare actually pays.
A markup ratio of 2.3x means for every $100 Medicare pays, this provider initially charges $230. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data